Skip to main content
SNY
NASDAQ Life Sciences

欧盟监管机构建议批准赛诺菲的Cenrifki用于继发性进展性多发性硬化症

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
8
Price
$47.45
Mkt Cap
$115.007B
52W Low
$43.32
52W High
$55.73
Market data snapshot near publication time

summarizeSummary

欧洲药品管理局的人用药品委员会（CHMP）已发出积极的意见，建议批准赛诺菲的Cenrifki（tolebrutinib）在欧盟获得批准。该药物旨在治疗无复发的继发性进展性多发性硬化症（SPMS），这是一种具有重大未满足医疗需求的残疾。基于HERCULES 3期研究的数据，该建议是欧盟市场授权的关键一步。这种积极的产品线发展增加了赛诺菲最近的连续好消息，包括强劲的第一季度盈利和其他积极的临床试验结果。预计欧盟委员会将在未来几个月内做出最终决定，这将成为股票的关键催化剂。

在该公告发布时，SNY的交易价格为$47.45，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1150.1亿。 52周交易区间为$43.32至$55.73。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed SNY - Latest Insights

SNY
Apr 29, 2026, 6:04 AM EDT
Filing Type: 6-K
Importance Score:
7
Sanofi Prices €2.3 Billion Multi-Tranche Bond Issue for General Corporate Purposes
Sentiment: Neutral
View Wiseek Article
SNY
Apr 27, 2026, 12:58 PM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Secures Key FDA Approvals for Dupixent and Tzield, Despite Sarclisa Delay
Sentiment: Positive
View Wiseek Article
SNY
Apr 24, 2026, 6:09 AM EDT
Source: GlobeNewswire
Importance Score:
8
EU Regulators Recommend Sanofi's Cenrifki for Secondary Progressive MS Approval
Sentiment: Positive
View Wiseek Article
SNY
Apr 23, 2026, 7:20 AM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Reports Strong Q1 Double-Digit Sales & EPS Growth, Multiple Regulatory Approvals, and Pipeline Advancements
Sentiment: Positive
View Wiseek Article
SNY
Apr 18, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability in Head-to-Head Study
Sentiment: Positive
View Wiseek Article
SNY
Apr 15, 2026, 6:57 AM EDT
Filing Type: 6-K
Importance Score:
8
Sanofi Reports Positive Phase 2 Lunsekimig Data and EU Approval for Dupixent in Young Children with CSU
Sentiment: Positive
View Wiseek Article
SNY
Apr 07, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Sanofi's Lunsekimig Meets Phase 2 Endpoints in Asthma and CRSwNP, Bolstering Respiratory Pipeline
Sentiment: Positive
View Wiseek Article
SNY
Mar 31, 2026, 12:19 PM EDT
Filing Type: 6-K
Importance Score:
7
Sanofi Reports Positive Phase 3 Amlitelimab Data for Atopic Dermatitis, Advances Pipeline
Sentiment: Positive
View Wiseek Article
SNY
Mar 31, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Sanofi's Rezurock Secures EU Conditional Approval for Chronic Graft-vs-Host Disease
Sentiment: Positive
View Wiseek Article
SNY
Mar 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
CHMP Recommends EU Approval for Sanofi's Innovative Sarclisa On-Body Injector for Multiple Myeloma
Sentiment: Positive
View Wiseek Article